Nucleus Pulposus‐Targeting Nanocarriers Facilitate Mirna‐Based Therapeutics for Intervertebral Disc Degeneration

Zhonghui Chen,Zhong Liao,Ming Liu,Fengfei Lin,Shunyou Chen,Geng Wang,Zhong Zheng,Boling Liu,Chaoxiong Li,Zheqiang Wang,Tianlai Chen,Hongzhe Huang,Qi Liao,Weiliang Cui

DOI: https://doi.org/10.1002/adhm.202301337

IF: 10

2023-08-27

Advanced Healthcare Materials

Abstract:Intervertebral disc degeneration (IDD) is a common cause of low back pain. Understanding its molecular mechanisms is the basis for developing specific treatment. To demonstrate that miR‐22‐3p is critical in the regulation of IDD, we conducted miRNA microarray analyses in conjunction with in vivo and in vitro experiments. The miR‐22‐3p knockout (KO) mice showed a marked decrease in the histological scores. Bioinformatic analysis revealed that miR‐22‐3p plays a mechanistic role in the development of IDD by targeting SIRT1, which in turn activates the JAK1/STAT3 signaling pathway. This was confirmed by a luciferase reporter assay and western blot analysis. Therapeutically, the delivery of miR‐22‐3p inhibitors and mimics through our synthesized nanoparticles in the IDD model alleviated and aggravated IDD, respectively. The nanocarriers enhanced transportation of miR‐22‐3p to nucleus pulposus (NP) cells, thus enabling the in vivo inhibition of miR‐22‐3p for therapeutic purposes and consequently promoting the development of miRNA‐specific drugs for IDD. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials